The longitudinal association of daily physical activity and symptoms of exacerbations in COPD patients Source: International Congress 2017 – Best abstracts in physical activity and management of COPD Year: 2017
Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002
The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019
Impact of nighttime and early morning symptoms on HRQoL and work productivity of COPD patients Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Reslizumab reduces severe exacerbations associated with emergency department visit or hospitalization and improves measures of lung function in patients on maintenance oral corticosteroids (OCS) at baseline Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Impact of short term supervised breathing exercises added to regular medications over nocturnal symptoms, requirement of rescue medication and spirometric variables in asthma patients Source: Annual Congress 2012 - Quality of life and clinical parametres in monitoring airway diseases Year: 2012
Impact of exacerbation of COPD on anxiety and depression symptoms and dyspnea in the activities of daily living Source: International Congress 2015 – Rehabilitation, exercise, hospitalisation and COPD Year: 2015
Evaluation of the relationship between the activity of daily living and dyspnoea in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 182s Year: 2005
Performance of activities of daily living as a predictor of rehospitalization for patients following an exacerbation of COPD Source: Annual Congress 2012 - The best posters on physical inactivity, muscle dysfunction and exercise intolerance Year: 2012
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Identification of COPD patient factors associated with nighttime and early morning symptoms Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Impact of physical activity level on symptomatology and functionality during an acute exacerbation in COPD patients. Source: International Congress 2018 – Exploring the importance of daily physical activity in chronic respiratory disease Year: 2018
Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
A comparison of arm exercise capacity and activities of daily living between well-controlled asthma patients with and without severe fatigue during daily life Source: Virtual Congress 2021 – Peripheral muscle function, exercise capacity and functional status in respiratory disease Year: 2021
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Correct use of meter dose inhaler device in relation to patient care, symptoms and disease exacerbations Source: Eur Respir J 2002; 20: Suppl. 38, 503s Year: 2002